Acasti Pharma Total Liabilities and Share Holders Equity 2014-2024 | GRCE

Acasti Pharma total liabilities and share holders equity from 2014 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Acasti Pharma Annual Total Liabilities and Share Holders Equity
(Millions of US $)
2024 $73
2023 $79
2022 $129
2021 $62
2020 $23
2019 $37
2018 $18
2017 $20
2016 $22
2015 $33
2015 $
2014 $44
2014 $
2013 $12
2013 $
Acasti Pharma Quarterly Total Liabilities and Share Holders Equity
(Millions of US $)
2024-06-30 $70
2024-03-31 $73
2023-12-31 $76
2023-09-30 $78
2023-06-30 $73
2023-03-31 $79
2022-12-31 $117
2022-09-30 $121
2022-06-30 $125
2022-03-31 $129
2021-12-31 $114
2021-09-30 $120
2021-06-30 $60
2021-03-31 $62
2020-12-31 $30
2020-09-30 $14
2020-06-30 $20
2020-03-31 $23
2019-12-31 $29
2019-09-30 $29
2019-06-30 $29
2019-03-31 $37
2018-12-31 $45
2018-09-30 $15
2018-06-30 $21
2018-03-31 $18
2017-12-31 $21
2017-09-30 $16
2017-06-30 $17
2017-02-28 $20
2016-11-30 $16
2016-08-31 $18
2016-05-31 $20
2016-03-31 $22
2016-02-29
2015-12-31 $23
2015-09-30 $26
2015-06-30 $28
2015-03-31 $33
2014-12-31 $35
2014-09-30 $38
2014-06-30 $40
2014-03-31 $44
2014-02-28
2013-12-31 $25
2013-09-30 $25
2013-06-30 $11
2013-03-31 $12
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00